

BD Announces Results For 2015 Fourth Fiscal Quarter And Full Year; Provides Fiscal 2016 Guidance

- Announces full fiscal year adjusted revenues of \$10.302 billion, an increase of 22.0 percent, or 29.5 percent on a currency-neutral basis. On a comparable, currency-neutral basis, adjusted revenues grew 5.3 percent for the full year. As reported, full-year revenues increased 21.7 percent to \$10.282 billion.

- For the full fiscal year, adjusted diluted earnings per share of \$7.16 increased 10.2 percent, or 21.2 percent on a currency-neutral basis. As reported, full-year diluted earnings per share were \$3.35.

- Expects full-year fiscal 2016 adjusted diluted earnings per share to be between \$8.37 and \$8.44 including the estimated unfavorable impact from foreign currency. This represents growth of approximately 17.0 to 18.0 percent. On a currency-neutral basis, full-year fiscal 2016 adjusted diluted earnings per share are expected to be between \$8.73 and \$8.80, which represents growth of 22.0 to 23.0 percent. These fiscal 2016 earnings per share expectations include approximately 22.0 percentage points of accretion from the CareFusion acquisition. As reported, the Company expects full fiscal year diluted earnings per share to be between \$6.57 and \$6.64.

PR Newswire

FRANKLIN LAKES, N.J., Nov. 4, 2015 [PRNewswire/](#) -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today reported quarterly adjusted revenues of \$3.067 billion for the fourth fiscal quarter ended September 30, 2015, an increase of 39.3 percent over the prior-year period as reported, or 49.1 percent on a currency-neutral basis. On a comparable, currency-neutral basis, fourth quarter adjusted revenues grew 5.1 percent. As reported, fourth quarter revenues were \$3.059 billion. For the full fiscal year ended September 30, 2015, BD reported adjusted revenues of \$10.302 billion, an increase of 22.0 percent over the prior-year period as reported, or 29.5 percent on a currency-neutral basis. On a comparable, currency-neutral basis, full fiscal year adjusted revenues grew 5.3 percent. As reported, full fiscal year revenues were \$10.282 billion.

"Fiscal 2015 was a significant year for BD with the successful completion of the largest acquisition in the Company's history," said Vincent A. Forlenza, Chairman, CEO and President. "We are very proud of our strong fourth quarter and fiscal year 2015 results, which exceeded our expectations. We enter fiscal 2016 with continued confidence in our ability to execute our strategy, deliver against our financial commitments, and return value to our shareholders."

All "comparable" basis revenue growth rates presented throughout this release include the results of CareFusion in the current and prior-year periods. For reconciliations of these revenue amounts and growth rates to the most directly comparable GAAP measures, please refer to the tables at the end of this release.

Fourth Quarter and Full Year Fiscal 2015 Operating Results

Adjusted diluted earnings per share were \$1.94, compared with \$1.74 in the prior-year period. This represents an increase of 11.5 percent, or 21.8 percent on a currency-neutral basis. On a reported basis, diluted earnings per share for the fourth quarter were \$0.84 compared with \$1.53 in the prior-year period.

For the full fiscal year ended September 30, 2015, adjusted diluted earnings per share were \$7.16, compared with \$6.50 in the prior-year period. This represents an increase of 10.2 percent, or 21.2 percent on a currency-neutral basis. On a reported basis, diluted earnings per share were \$3.35, compared with \$5.99 in the prior-year period.

Current and prior-year adjusted results exclude the impact of the non-cash amortization of intangible assets and other certain specified items. These specified items are detailed in the accompanying reconciliation of reported diluted earnings per share to adjusted diluted earnings per share.

Segment Results

In the BD Medical segment, worldwide adjusted revenues for the quarter were \$2.091 billion, an increase of 75.3 percent over the prior-year period as reported, or 86.6 percent on a currency-neutral basis. On a comparable, currency-neutral basis, adjusted Medical revenues grew 5.2 percent, which reflects strong sales across the Medication Management Solutions, Medication and Procedural Solutions, Pharmaceutical Systems, and Diabetes Care units, partially offset by a decline in the Respiratory Solutions unit. On a reported basis, Medical revenues were \$2.083 billion.

For the twelve-month period ended September 30, 2015, BD Medical adjusted revenues of \$6.480 billion increased 41.7 percent over the prior-year period as reported, or 50.2 percent on a currency-neutral basis. On a comparable, currency-neutral basis, adjusted revenues grew 5.5 percent. On a reported basis, revenues were \$6.460 billion.

In the BD Life Sciences segment, worldwide revenues for the quarter were \$976 million, a decrease of 3.3 percent from the prior-year period, or an increase of 4.8 percent on a currency-neutral basis. The segment's results reflect solid growth in the Preanalytical Systems and Diagnostic Systems units, and moderate growth in the Biosciences unit.

For the twelve-month period ended September 30, 2015, BD Life Sciences revenues of \$3.822 billion decreased 1.3 percent from the prior-year period, and increased 5.0 percent on a currency-neutral basis.

Geographic Results

Fourth quarter adjusted revenues in the U.S. of \$1.640 billion represent an increase of 88.3 percent over the prior-year period as reported. On a comparable basis, adjusted U.S. revenues increased 4.6 percent. Within the BD Medical segment, growth was driven by strong sales in the Medication Management Solutions and Medication and Procedural Solutions units, partially offset by a decline in the Respiratory Systems unit. Growth in the BD Life Sciences segment was driven by strong performance in the Biosciences unit. On a reported basis, U.S. revenues were \$1.632 billion.

Revenues outside of the U.S. were \$1.427 billion, representing an increase of 7.2 percent over the prior-year period, or an increase of 23.4 percent on a currency-neutral basis. On a comparable, currency-neutral basis, international revenues grew 5.5 percent which reflects continued strength in Western Europe.

For the twelve-month period ended September 30, 2015, adjusted revenues in the U.S. were \$5.090 billion, an increase of 49.0 percent over the prior-year period as reported. On a comparable basis, U.S. revenues grew 4.1 percent. On a reported basis, U.S. revenues were \$5.069 billion. Revenues outside of the U.S. were \$5.213 billion, an increase of 3.6 percent over the prior-year period as reported, or an increase of 16.2 percent on a currency-neutral basis. On a comparable, currency-neutral basis, revenues outside the U.S. grew 6.6 percent.

Fiscal 2016 Outlook for Full Year

The Company estimates that currency-neutral adjusted revenues for the full fiscal year 2016, including the accretion from the acquisition of CareFusion, will increase 24.5 to 25.0 percent. Including the impact of foreign currency, adjusted revenues are expected to increase 23.0 to 23.5 percent. On a comparable, currency-neutral basis, the Company estimates organic adjusted revenues will increase 4.5 to 5.0 percent. As reported, the Company expects full fiscal year revenues to increase 23.0 to 23.5 percent.

The Company expects adjusted diluted earnings per share to be between \$8.37 and \$8.44 for the full fiscal year 2016 including the estimated unfavorable impact from foreign currency. This represents growth of approximately 17.0 to 18.0 percent. On a currency-neutral basis, full-year fiscal 2016 adjusted diluted earnings per share are expected to be between \$8.73 and \$8.80, which represents growth of 22.0 to 23.0 percent over 2015 adjusted diluted earnings per share of \$7.16. Adjusted diluted earnings per share exclude, among other specified items, the non-cash amortization of intangible assets, and include approximately 22.0 percentage points of accretion from the CareFusion acquisition. As reported, the Company expects full fiscal year diluted earnings per share to be between \$6.57 and \$6.64.

Conference Call Information

A conference call regarding BD's fourth quarter results will be broadcast live on BD's website www.bd.com/investors, along with related slides, at 8:00 a.m. (ET) Wednesday, November 4, 2015. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 1-800-585-8367 (domestic) and 1-404-537-3406 (international) through the close of business on Wednesday, November 11, 2015, confirmation number 51724857.

Non-GAAP Financial Measures/Financial Tables

This news release contains certain non-GAAP financial measures. Reconciliations of these and other non-GAAP measures to the comparable GAAP measures are included in the attached financial tables. Within the attached financial tables presented, certain columns and rows may not add due to the use of rounded numbers. Percentages and earnings per share amounts presented are calculated from the underlying amounts.

About BD

BD is a leading medical technology company that partners with customers and stakeholders to address many of the world's most pressing and evolving health needs. Our innovative solutions are focused on improving medication management and patient safety; supporting infection prevention practices; equipping surgical and interventional procedures; improving drug delivery; aiding anesthesia and respiratory care; advancing cellular research and applications; enhancing the diagnosis of infectious diseases and cancers; and supporting the management of diabetes. We are more than 45,000 associates in 50 countries who strive to fulfill our purpose of "Helping all people live healthy lives" by advancing the quality, accessibility, safety and affordability of healthcare around the world. In 2015, BD welcomed CareFusion and its products into the BD family of solutions. For more information on BD, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2016 Outlook for Full Year", contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues and earnings per share. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially. These factors include, but are not limited to: risks relating to the integration of CareFusion's operations, products and employees into BD and the possibility that the anticipated synergies and other benefits of the proposed acquisition will not be realized or will not be realized within the expected timeframe; potential cuts in governmental healthcare spending, which could result in reduced demand for our product or downward pricing pressure; measures to contain healthcare costs; adverse changes in regional, national or foreign economic conditions, including any impact on our ability to access credit markets and finance our operations, the demand for our products and services as a result of reduced government funding, lower utilization rates or otherwise, or our

suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates; our ability to successfully integrate any businesses we acquire; the adverse impact of cyber-attacks on our information systems; competitive factors including technological advances and new products introduced by competitors; pricing and market pressures; difficulties inherent in product development, delays in product introductions and uncertainty of market acceptance of new products; increases in energy costs and their effect on, among other things, the cost of producing BD's products; efficacy or safety concerns relating to product recalls; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; new or changing laws and regulations impacting our business or changes in enforcement practices with respect to such laws; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); future healthcare reform, including changes in government pricing and reimbursement policies or other cost containment reforms; the effects of potential pandemic diseases; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON
DICKINSON
AND COMPANY

CONSOLIDATED
INCOME
STATEMENTS

(Unaudited;
Amounts in
millions,
except
share and
per share
data)

Three Months Ended September 30,

	2015	2014	% Change
	----	-----	
REVENUES	\$3,059	\$2,202	38.9
Cost of products sold	1,630	1,099	48.2
Selling and administrative expense	756	561	34.8
Research and development expense	196	140	39.6
Acquisition-related costs	182	-	NM
-----	---	---	---
TOTAL OPERATING COSTS			
AND EXPENSES	2,764	1,801	53.5
-----	-----	-----	
OPERATING INCOME	296	401	(26.3)
Interest expense	(99)	(36)	NM
Interest income	(5)	10	NM
Other (expense) income, net	(2)	1	NM
-----	---	---	---
INCOME BEFORE INCOME TAXES	190	376	(49.6)
Income tax provision	9	76	(88.4)
-----	---	---	---
NET INCOME	\$181	\$301	(39.9)
-----	-----	-----	
EARNINGS PER SHARE			
Basic Earnings per Share	\$0.86	\$1.56	(44.9)

Diluted Earnings per Share	\$0.84	\$1.53	(45.1)
----------------------------------	--------	--------	--------

AVERAGE
SHARES
OUTSTANDING
(in
thousands)

Basic	210,985	192,332
Diluted	215,719	196,460

NM -Not
Meaningful

BECTON
DICKINSON
AND
COMPANY

CONSOLIDATED
INCOME
STATEMENTS

(Unaudited;
Amounts in
millions,
except
share and
per share
data)

Twelve Months Ended September 30,

	2015	2014	% Change
	----	-----	
REVENUES	\$10,282	\$8,446	21.7
Cost of products sold	5,587	4,145	34.8
Selling and administrative expense	2,563	2,145	19.5
Research and development expense	632	550	14.8
Acquisition- related costs	426	-	NM
	----	---	---
TOTAL OPERATING COSTS			
AND EXPENSES	9,207	6,840	34.6
	-----	----	
OPERATING INCOME	1,074	1,606	(33.1)
Interest expense	(371)	(135)	NM
Interest income	15	46	(67.0)
Other income, net	21	5	NM
	----	---	---
INCOME BEFORE INCOME TAXES	739	1,522	(51.4)

Income tax provision	44	337	(87.0)
-----	---	---	-----
NET INCOME	\$695	\$1,185	(41.3)
-----	---	-----	-----

EARNINGS
PER SHARE

Basic Earnings per Share	\$3.43	\$6.13	(44.0)
Diluted Earnings per Share	\$3.35	\$5.99	(44.1)
-----	-----	-----	-----

AVERAGE
SHARES
OUTSTANDING
(in thousands)

Basic	202,537	193,299
Diluted	207,509	197,709
-----	-----	-----

NM -Not
Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

Three Months Ended September 30,

(Unaudited; Amounts in millions)

	A	B	C	D=(A-B)/B	E=(C-B)/B
	---	---	---	-----	-----
	As Reported	Adjusted	% Change		
	-----	-----	-----		
	2015	2014	2015	Reported	Adjusted
	---	---	---	-----	-----
BD MEDICAL					

Medication and Procedural Solutions		\$481	\$257	\$481	87.0
Medication Management Solutions		390	-	390	NM
Diabetes Care		130	123	130	5.7
Pharmaceutical Systems		78	76	78	2.5
Respiratory Solutions		133	-	133	NM
Deferred Revenue Adjustment *		(8)	-	-	NM
TOTAL		\$1,203	\$456	\$1,211	164.1
-----		-----	-----	-----	-----
BD LIFE SCIENCES					

Preanalytical Systems		\$173	\$171	\$173	1.5
Diagnostic Systems		146	148	146	(1.8)
Biosciences		110	96	110	14.5
-----		---	---	---	---
TOTAL		\$429	\$415	\$429	3.3
-----		-----	-----	-----	-----
TOTAL UNITED STATES		\$1,632	\$871	\$1,640	87.4
-----		-----	-----	-----	-----

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C	D=(A-B)/B	E=(A-B-C)/B	
	---	---	---	-----	-----	
	As Reported	FX		% Change		
	-----			-----		
	2015	2014	Impact	Reported	FXN	
	---	---	---	-----	---	
BD MEDICAL						

Medication and Procedural Solutions		\$356	\$331	\$(52)	7.6	23.3
Medication Management Solutions			89	-	(14)	NM NM
Diabetes Care		127	141	(23)	(10.2)	6.0
Pharmaceutical Systems			254	265	(39)	(4.0) 10.8
Respiratory Solutions			54	-	(6)	NM NM
TOTAL		\$880	\$737	\$(134)	19.4	37.6
----		----	----	-----	----	

BD LIFE SCIENCES

Prealalytical Systems		\$175	\$187	\$(30)	(6.4)	9.8
Diagnostic Systems		196	202	(29)	(2.9)	11.5
Biosciences		176	205	(22)	(14.3)	(3.5)
----		---	---			
TOTAL		\$547	\$594	\$(81)	(7.9)	5.8
----		----	----	-----	----	

TOTAL INTERNATIONAL		\$1,427	\$1,331	\$(216)	7.2	23.4
-----		-----	-----	-----		

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C	D	E=(A-B)/B	F=(A-B-D)/B	G=(C-B)/B
	---	---	---	---	-----	-----	-----
						% Change	

	As Reported	Adjusted	FX				

	2015	2014	2015	Impact	Reported	FXN	Adjust
	---	---	---	-----	-----	---	-----
BD MEDICAL							

Medication and Procedural Solutions	\$836	\$588	\$836	\$(52)	42.3
Medication Management Solutions	479	-	479	(14)	NM
Diabetes Care	257	264	257	(23)	(2.8)
Pharmaceutical Systems	332	341	332	(39)	(2.6)
Respiratory Solutions	187	-	187	(6)	NM
Deferred Revenue Adjustment *	(8)	-	-	-	NM
TOTAL	\$2,083	\$1,193	\$2,091	\$(134)	74.7
-----	-----	-----	-----	-----	-----
BD LIFE SCIENCES					

Preanalytical Systems	\$349	\$358	\$349	\$(30)	(2.6)
Diagnostic Systems	342	350	342	(29)	(2.4)
Biosciences	286	301	286	(22)	(5.1)
-----	---	---	---	---	---
TOTAL	\$976	\$1,009	\$976	\$(81)	(3.3)
-----	-----	-----	-----	-----	-----
TOTAL REVENUES	\$3,059	\$2,202	\$3,067	\$(216)	38.9
-----	-----	-----	-----	-----	-----

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferral of these contracts is typically deferred and recognized over the term of the contracts.

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - UNITED STATES

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)

	A	B	C	D=(A-B)/B	E=(C-B)/B
	-----	---	---	-----	-----
	As Reported	Adjusted		% Change	
	-----	-----	-----	-----	-----
	2015	2014	2015	Reported	Adjusted
	---	---	---	-----	-----
BD MEDICAL					

Medication and Procedural Solutions	\$1,483	\$1,016	\$1,483	46.0	46.0
Medication Management Solutions	832	-	832	NM	NM
Diabetes Care	491	481	491	2.2	2.2
Pharmaceutical Systems	304	303	304	0.3	0.3
Respiratory Solutions	297	-	297	NM	NM
Deferred Revenue Adjustment *	(20)	-	-	NM	-
TOTAL	\$3,386	\$1,799	\$3,407	88.2	89.4
-----	-----	-----	-----	-----	-----
BD LIFE SCIENCES					

Preanalytical Systems	\$689	\$678	\$689	1.7	1.7
Diagnostic Systems	592	573	592	3.1	3.1
Biosciences	402	366	402	9.7	9.7
-----	---	---	---	---	---

TOTAL	\$1,683	\$1,617	\$1,683	4.0	4.0
TOTAL UNITED STATES	\$5,069	\$3,417	\$5,090	48.4	49.0

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred software maintenance contracts in the United States. Revenues for these contracts is typically deferred and recognized over the term of the contracts.

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - INTERNATIONAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C	D=(A-B)/B	E=(A-B-C)/B
	As Reported	FX	% Change		
	2015	2014	Impact	Reported	FXN
BD MEDICAL					
Medication and Procedural Solutions	\$1,367	\$1,292		\$(147)	5.8 17.2
Medication Management Solutions		201	-	(34)	NM NM
Diabetes Care	521	557	(69)	(6.5)	6.0
Pharmaceutical Systems	863	926	(124)	(6.8)	6.7
Respiratory Solutions	122	-	(14)	NM	NM
TOTAL	\$3,074	\$2,774	\$(389)	10.8	24.8

BD LIFE SCIENCES

Preanalytical Systems	\$701	\$734	\$(90)	(4.5)	7.8
Diagnostic Systems	708	728	(84)	(2.8)	8.7
Biosciences	730	793	(69)	(7.9)	0.8
TOTAL	\$2,139	\$2,255	\$(244)	(5.1)	5.7

TOTAL INTERNATIONAL	\$5,213	\$5,029	\$(633)	3.6	16.2
---------------------	---------	---------	---------	-----	------

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

REVENUES BY BUSINESS SEGMENTS AND UNITS - TOTAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C	D	E=(A-B)/B	F=(A-B-D)/B
	As Reported	Adjusted	FX			% Change

	2015	2014	2015	Impact	Reported	FXN
BD MEDICAL						
Medication and Procedural Solutions		\$2,850		\$2,307	\$2,850	\$(147)
Medication Management Solutions		1,033		-	1,033	(34)
Diabetes Care		1,012		1,037	1,012	(69)
Pharmaceutical Systems		1,167		1,229	1,167	(124)
Respiratory Solutions		419		-	419	(14)
Deferred Revenue Adjustment *		(20)		-	-	-
TOTAL		\$6,460		\$4,573	\$6,480	\$(389)
BD LIFE SCIENCES						
Preanalytical Systems		\$1,391		\$1,412	\$1,391	\$(90)
Diagnostic Systems		1,299		1,301	1,299	(84)
Biosciences		1,132		1,159	1,132	(69)
TOTAL		\$3,822		\$3,872	\$3,822	\$(244)
TOTAL REVENUES		\$10,282		\$8,446	\$10,302	\$(633)

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred recognized over the term of the contracts.

NM - Not Meaningful

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED REVENUE CHANGE - UNITED STATES

Three Months Ended September 30,

(Unaudited; Amounts in millions)

	A	B	C=A+B	D	E	F=D+E
		Deferred			BD	CFN
	Reported	Revenue	Adjusted	Reported	Reported	Historical
	2015	Adjustment	2015	2014	2014	2014
BD MEDICAL						
Medication and Procedural Solutions		\$481	\$ -	\$481		\$257
Medication Management Solutions		390	-	390		-
Diabetes Care		130	-	130		123
Pharmaceutical Systems		78	-	78		76
Respiratory Solutions		133	-	133		-
Deferred Revenue Adjustment *		(8)	8	-		-
TOTAL		\$1,203	\$8	\$1,211		\$456
BD LIFE SCIENCES						
Preanalytical Systems		\$173	\$ -	\$173		\$171
Diagnostic Systems		146	-	146		148

Biosciences	110	-	110	96
TOTAL	\$429	\$ -	\$429	\$415
-----	----	----	----	----
TOTAL UNITED STATES	\$1,632	\$8	\$1,640	\$871
-----	-----	----	-----	-----

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred revenue was then recognized over the term of the contracts.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE FXN REVENUE CHANGE - INTERNATIONAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C	D=B+C	E	F=(A-D-E)/D	
	Reported	BD Reported	CFN Reported	Comparable Historical	Comparable FX Impact	Comparable FXN % Change	
	2015	2014	2014	2014			
-----	----	----	----	----	-----	-----	-----
BD MEDICAL							
Medication and Procedural Solutions			\$356	\$331	\$60	\$391	\$(52) 4.5
Medication Management Solutions			89	-	97	97	(14) 5.5
Diabetes Care		127	141	-	141	(23)	6.0
Pharmaceutical Systems		254	265	-	265	(39)	10.8
Respiratory Solutions		54	-	69	69	(6)	(12.2)
TOTAL		\$880	\$737	\$226	\$963	\$(134)	5.4
-----	-----	-----	-----	-----	-----	-----	-----
BD LIFE SCIENCES							
Preanalytical Systems		\$175	\$187	\$ -	\$187	\$(30)	9.8
Diagnostic Systems		196	202	-	202	(29)	11.5
Biosciences		176	205	-	205	(22)	(3.5)
TOTAL		\$547	\$594	\$ -	\$594	\$(81)	5.8
-----	-----	-----	-----	-----	-----	-----	-----
TOTAL INTERNATIONAL		\$1,427	\$1,331	\$226	\$1,557	\$(216)	5.5
-----	-----	-----	-----	-----	-----	-----	-----

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED FXN REVENUE CHANGE - TOTAL

Three Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C=A+B	D	E	F=D+E
	Reported	Deferred Revenue	Adjusted	Reported	BD	CFN
	2015	Adjustment	2015	2014		2014
-----	-----	-----	-----	-----	-----	-----
BD MEDICAL						
Medication and Procedural Solutions						
Medication Management Solutions						
Diabetes Care						
Pharmaceutical Systems						
Respiratory Solutions						
TOTAL						
-----	-----	-----	-----	-----	-----	-----
BD LIFE SCIENCES						
Preanalytical Systems						
Diagnostic Systems						
Biosciences						
TOTAL						
-----	-----	-----	-----	-----	-----	-----
TOTAL INTERNATIONAL						
-----	-----	-----	-----	-----	-----	-----

Medication and Procedural Solutions	\$836	\$ -	\$836	\$588
Medication Management Solutions	479	-	479	-
Diabetes Care	257	-	257	264
Pharmaceutical Systems	332	-	332	341
Respiratory Solutions	187	-	187	-
Deferred Revenue Adjustment *	(8)	8	-	-
TOTAL	\$2,083	\$8	\$2,091	\$1,193

BD LIFE SCIENCES

Preanalytical Systems	\$349	\$ -	\$349	\$358
Diagnostic Systems	342	-	342	350
Biosciences	286	-	286	301
TOTAL	\$976	\$ -	\$976	\$1,009

TOTAL REVENUES	\$3,059	\$8	\$3,067	\$2,202
----------------	---------	-----	---------	---------

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred revenue was written down to reflect the fair value of the contracts.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED REVENUE CHANGE - UNITED STATES

Twelve Months Ended September 30,

(Unaudited; Amounts in millions)

A	B	C=A+B	D	E=C+D	F
Reported	Deferred Revenue	Adjusted	Reported	CFN	Comparable
2015	Adjustment	2015	1st Half 2015	2015	2014
		**			2014

BD MEDICAL

Medication and Procedural Solutions	\$1,483	\$ -	\$1,483	\$427
Medication Management Solutions	832	-	832	843
Diabetes Care	491	-	491	-
Pharmaceutical Systems	304	-	304	-
Respiratory Solutions	297	-	297	333
Deferred Revenue Adjustment *	(20)	20	-	-
TOTAL	\$3,386	\$20	\$3,407	\$1,603

BD LIFE SCIENCES

Preanalytical Systems	\$689	\$ -	\$689	\$ -
Diagnostic Systems	592	-	592	-
Biosciences	402	-	402	-
TOTAL	\$1,683	\$ -	\$1,683	\$ -

TOTAL UNITED STATES	\$5,069	\$20	\$5,090	\$1,603
---------------------	---------	------	---------	---------

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferral of the contracts.

** For the quarters ended December 31, 2014 and March 31, 2015

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE FXN REVENUE CHANGE - INTERNATIONAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C=A+B	D	E	F=D+E	G	H=(C-F-G)/F
	Reported	Reported	Historical	Reported	Reported	Reported	Historical	FX
	2015	1st Half 2015	2015	2014	2014	2014	Impact	% Change
		*						
BD MEDICAL								
Medication and Procedural Solutions		\$1,367		\$117		\$1,483	\$1,292	\$240
Medication Management Solutions		201		208		409	-	416
Diabetes Care		521	-		521		557	(69) 6.0
Pharmaceutical Systems		863	-		863		926	(69) 6.7
Respiratory Solutions		122	138		260		-	267
TOTAL		\$3,074	\$463		\$3,536		\$2,774	\$923
BD LIFE SCIENCES								
Preanalytical Systems		\$701	\$ -		\$701		\$734	\$ -
Diagnostic Systems		708	-		708		728	-
Biosciences		730	-		730		793	-
TOTAL		\$2,139	\$ -		\$2,139		\$2,255	\$ -
TOTAL INTERNATIONAL		\$5,213		\$463		\$5,675		\$5,029

* For the quarters ended December 31, 2014 and March 31, 2015

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED REVENUE CHANGE TO COMPARABLE ADJUSTED FXN REVENUE CHANGE - TOTAL

Twelve Months Ended September 30, (continued)

(Unaudited; Amounts in millions)

	A	B	C=A+B	D	E=C+D
	Reported	Deferred Revenue	Adjusted	Reported	Adjusted
	2015	Adjustment	2015	1st Half 2015	2015
			**		

BD MEDICAL

Medication and Procedural Solutions	\$2,850	\$	-	\$2,850
Medication Management Solutions	1,033		-	1,033
Diabetes Care	1,012	-		1,012
Pharmaceutical Systems	1,167	-		1,167
Respiratory Solutions	419	-		419
Deferred Revenue Adjustment *	(20)	20		-
TOTAL	\$6,460	\$20		\$6,480

BD LIFE SCIENCES

Preanalytical Systems	\$1,391	\$	-	\$1,391	\$
Diagnostic Systems	1,299		-	1,299	
Biosciences	1,132		-	1,132	
TOTAL	\$3,822	\$	-	\$3,822	\$

TOTAL REVENUES	\$10,282	\$20		\$10,302
----------------	----------	------	--	----------

* In accordance with U.S. GAAP business combination accounting rules, CareFusion's deferred revenue balance was written down to reflect a fair value measurement as of the acquisition date. The deferred revenue balance was \$20 million as of September 30, 2014.

** For the quarters ended December 31, 2014 and March 31, 2015

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL REVENUE INFORMATION

SAFETY REVENUES

(Unaudited; Amounts in millions)

Three Months Ended September 30,					
A	B	C	D=(A-B)/B	E=(A-B-C)/B	
As Reported	FX		% Change		
2015	2014	Impact	Reported	FXN	
TOTAL SAFETY REVENUES					
United States	\$441	\$301	\$ -	46.6	46.6
International	303	265	(49)	14.1	32.7
TOTAL	\$744	\$566	\$(49)	31.3	40.0
BY SEGMENT					
BD Medical	\$468	\$287	\$(26)	63.3	72.4
BD Life Sciences	276	279	(23)	(1.4)	6.8
TOTAL	\$744	\$566	\$(49)	31.3	40.0

1000 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 1022 1023 1024 1025 1026 1027 1028 1029 1030 1031 1032 1033 1034 1035 1036 1037 1038 1039 1040 1041 1042 1043 1044 1045 1046 1047 1048 1049 1050 1051 1052 1053 1054 1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067 1068 1069 1070 1071 1072 1073 1074 1075 1076 1077 1078 1079 1080 1081 1082 1083 1084 1085 1086 1087 1088 1089 1090 1091 1092 1093 1094 1095 1096 1097 1098 1099 1100 1101 1102 1103 1104 1105 1106 1107 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 1129 1130 1131 1132 1133 1134 1135 1136 1137 1138 1139 1140 1141 1142 1143 1144 1145 1146 1147 1148 1149 1150 1151 1152 1153 1154 1155 1156 1157 1158 1159 1160 1161 1162 1163 1164 1165 1166 1167 1168 1169 1170 1171 1172 1173 1174 1175 1176 1177 1178 1179 1180 1181 1182 1183 1184 1185 1186 1187 1188 1189 1190 1191 1192 1193 1194 1195 1196 1197 1198 1199 1200 1201 1202 1203 1204 1205 1206 1207 1208 1209 1210 1211 1212 1213 1214 1215 1216 1217 1218 1219 1220 1221 1222 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 1244 1245 1246 1247 1248 1249 1250 1251 1252 1253 1254 1255 1256 1257 1258 1259 1260 1261 1262 1263 1264 1265 1266 1267 1268 1269 1270 1271 1272 1273 1274 1275 1276 1277 1278 1279 1280 1281 1282 1283 1284 1285 1286 1287 1288 1289 1290 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 1312 1313 1314 1315 1316 1317 1318 1319 1320 1321 1322 1323 1324 1325 1326 1327 1328 1329 1330 1331 1332 1333 1334 1335 1336 1337 1338 1339 1340 1341 1342 1343 1344 1345 1346 1347 1348 1349 1350 1351 1352 1353 1354 1355 1356 1357 1358 1359 1360 1361 1362 1363 1364 1365 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 1387 1388 1389 1390 1391 1392 1393 1394 1395 1396 1397 1398 1399 1400 1401 1402 1403 1404 1405 1406 1407 1408 1409 1410 1411 1412 1413 1414 1415 1416 1417 1418 1419 1420 1421 1422 1423 1424 1425 1426 1427 1428 1429 1430 1431 1432 1433 1434 1435 1436 1437 1438 1439 1440 1441 1442 1443 1444 1445 1446 1447 1448 1449 1450 1451 1452 1453 1454 1455 1456 1457 1458 1459 1460 1461 1462 1463 1464 1465 1466 1467 1468 1469 1470 1471 1472 1473 1474 1475 1476 1477 1478 1479 1480 1481 1482 1483 1484 1485 1486 1487 1488 1489 1490 1491 1492 1493 1494 1495 1496 1497 1498 1499 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 1521 1522 1523 1524 1525 1526 1527 1528 1529 1530 1531 1532 1533 1534 1535 1536 1537 1538 1539 1540 1541 1542 1543 1544 1545 1546 1547 1548 1549 1550 1551 1552 1553 1554 1555 1556 1557 1558 1559 1560 1561 1562 1563 1564 1565 1566 1567 1568 1569 1570 1571 1572 1573 1574 1575 1576 1577 1578 1579 1580 1581 1582 1583 1584 1585 1586 1587 1588 1589 1590 1591 1592 1593 1594 1595 1596 1597 1598 1599 1600 1601 1602 1603 1604 1605 1606 1607 1608 1609 1610 1611 1612 1613 1614 1615 1616 1617 1618 1619 1620 1621 1622 1623 1624 1625 1626 1627 1628 1629 1630 1631 1632 1633 1634 1635 1636 1637 1638 1639 1640 1641 1642 1643 1644 1645 1646 1647 1648 1649 1650 1651 1652 1653 1654 1655 1656 1657 1658 1659 1660 1661 1662 1663 1664 1665 1666 1667 1668 1669 1670 1671 1672 1673 1674 1675 1676 1677 1678 1679 1680 1681 1682 1683 1684 1685 1686 1687 1688 1689 1690 1691 1692 1693 1694 1695 1696 1697 1698 1699 1700 1701 1702 1703 1704 1705 1706 1707 1708 1709 1710 1711 1712 1713 1714 1715 1716 1717 1718 1719 1720 1721 1722 1723 1724 1725 1726 1727 1728 1729 1730 1731 1732 1733 1734 1735 1736 1737 1738 1739 1740 1741 1742 1743 1744 1745 1746 1747 1748 1749 1750 1751 1752 1753 1754 1755 1756 1757 1758 1759 1760 1761 1762 1763 1764 1765 1766 1767 1768 1769 1770 1771 1772 1773 1774 1775 1776 1777 1778 1779 1780 1781 1782 1783 1784 1785 1786 1787 1788 1789 1790 1791 1792 1793 1794 1795 1796 1797 1798 1799 1800 1801 1802 1803 1804 1805 1806 1807 1808 1809 1810 1811 1812 1813 1814 1815 1816 1817 1818

BY SEGMENT

BECTON DICKINSON AND COMPANY

RECONCILIATION OF SAFETY REVENUE CHANGE TO COMPARABLE FXN REVENUE CHANGE

BY SEGMENT

A	B	C=A+B	D	E	F=D+E	G	H=(C-F-G)/F
---	---	-----	---	---	-----	---	-----
	CFN	Comparable	BD	CFN	Comparable	Comparable	Cor
Reported	Reported	Historical	Reported	Reported	Historical	FX	FXN
2015	1st Half 2015	2015	2014	2014	2014	Impact	% Change
	*						

TOTAL SAFETY REVENUES

United States	\$1,471	\$252	\$1,722	\$1,207	\$470	\$
International	1,128	83	1,210	1,016	172	1,188
TOTAL	\$2,598	\$334	\$2,932	\$2,223	\$641	\$2,1

BY SEGMENT

BD Medical	\$1,501	\$334	\$1,835	\$1,119	\$641	\$
BD Life Sciences	1,097	-	1,097	1,104	-	1,104
TOTAL	\$2,598	\$334	\$2,932	\$2,223	\$641	\$2,1

* For the quarters ended December 31, 2014 and March 31, 2015

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)

	Three Months Ended September 30,			
	2015	2014	Growth	Translation
Reported Diluted Earnings per Share		\$0.84		\$1.53
Transaction Costs (\$7 million or \$4 million after-tax and \$6 million or \$4 million after-tax, respectively) (1)			0.02	0.02
Integration Costs (\$40 million or \$25 million after-tax) (1)		0.12		-
Restructuring Costs (\$135 million or \$84 million after-tax) (1)		0.39		-
Purchase Accounting Adjustments (\$179 million or \$125 million after-tax and \$18 million or \$13 million after-tax, respectively)			0.58	(2) 0.06
Employee Termination Cost-related Amounts (\$36 million or \$23 million after-tax) (4)			-	0.12
Research and Development Adjustment (\$4) million or \$(2) million after-tax) (5)			-	(0.01)
Pension Settlement Charges (\$3 million or \$2 million after-tax) (6)		-		0.01
Other Specified Items, Net (\$5 million or \$3 million after-tax) (7)		-		0.02
Adjusted Diluted Earnings per Share		\$1.94		\$1.74

(1) Represents transaction, integration and restructuring costs associated with the CareFusion acquisition.

(2) Represents non-cash amortization expense of \$152 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase acco

(3) Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.

(4) Represents amounts recorded to a liability for employee termination costs associated with workforce reduction actions taken in the fourth quarter of fiscal year 2014.

(5) Represents a revision to the estimated probable loss previously recorded as a result of the decision to terminate a research and development program in the Medical segment.

(6) Represents non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company's U.S. supplemental pension plan, as such payments exceeded the servi

(7) Represents a charge resulting from the adjustment to the carrying amount of an asset that is being held for sale.

BECTON DICKINSON AND COMPANY

SUPPLEMENTAL INFORMATION

RECONCILIATION OF REPORTED DILUTED EPS TO ADJUSTED DILUTED EPS

(Unaudited)

	Twelve Months Ended September 30,			
	2015	2014	Growth	Translation
	----	----	-----	-----
Reported Diluted Earnings per Share		\$3.35		\$5.99
Financing Costs (\$107 million or \$65 million after-tax) (1)		0.31		-
Transaction Costs (\$59 million or \$39 million after-tax and \$6 million or \$4 million after-tax, respectively) (1)			0.19	0.02
Integration Costs (\$95 million or \$59 million after-tax) (1)		0.29		-
Restructuring Costs (\$271 million or \$167 million after-tax) (1)		0.80		-
Purchase Accounting Adjustments (\$645 million or \$451 million after-tax and \$74 million or \$51 million after-tax, respectively)			2.17	(2) 0.26
Employee Termination Cost-related Amounts (\$5 million or \$(3) million after-tax and \$36 million or \$23 million after-tax, respectively) (4)				(0.01)
Litigation-related Charge (\$12 million or \$7 million after-tax) (5)		0.04		-
Dilutive Share Impact (6)		0.02		-
Research and Development Charges (\$26 million or \$16 million after-tax) (7)			-	0.08
Pension Settlement Charges (\$3 million or \$2 million after-tax) (8)		-		0.01
Other Specified Items, Net (\$8 million or \$6 million after-tax) (9)		-		0.03
Adjusted Diluted Earnings per Share		\$7.16		\$6.50

(1) Represents financing, transaction, integration and restructuring costs associated with the CareFusion acquisition.

(2) Represents non-cash amortization expense of \$336 million pre-tax associated with acquisition related identifiable intangible assets, including CareFusion, as well as the net amortization of purchase acco gain on a previously held investment in CRIS1 Medical Systems, Inc. of \$9 million pre-tax.

(3) Represents non-cash amortization expense associated with acquisition related identifiable intangible assets.

(4) Represents amounts recorded to a liability for employee termination costs associated with workforce reduction actions taken in the fourth quarter of fiscal year 2014.

(5) Represents a charge for plaintiff's attorneys' fees associated with the unfavorable verdict in the antitrust and false advertising lawsuit filed against BD by RTI.

(6) Represents the dilutive impact of BD shares issued as part of purchase consideration for CareFusion acquisition prior to the consolidation of its operating results beginning on April 1, 2015. The year-to-di

(7) Includes a \$6 million charge associated with the decision to terminate a research and development program in the Medical segment; the charge relates to program asset write-offs and obligations. Also in the Life Sciences segment.

(8) Primarily represents non-cash pension settlement charges associated with lump sum benefit payments made primarily from the Company's U.S. supplemental pension plan, as such payments exceeded

(9) Represents the cost associated with the decision to early terminate a European distributor arrangement in the Life Sciences segment of \$11 million pre-tax and a charge resulting from the adjustment to ti

FY2016 OUTLOOK RECONCILIATION

	FY2016 Outlook							
	Revenues	FX Impact	FXN Basis					
Full Year FY2016 Estimated Growth on a Reported Basis	23.0% - 23.5%		~(1.5%)		24.5% - 25.0%			
Deferred Revenue Adjustment	NM		NM		NM			
Adjusted Full Year FY2016 Estimated Growth	23.0% - 23.5%		~(1.5%)		24.5% - 25.0%			
	Full Year	Full Year						
	FY2016	FY2015	% Increase					
	(estimated)							
Reported Fully Diluted Earnings per Share	\$	6.57 - 6.64		\$3.35		NM		
Financing Costs		-		0.31				
Transaction Costs		-		0.19				
Integration Costs		-		0.29				
Restructuring Costs		-		0.80				
Purchase Accounting Adjustments		1.80		2.17				
Employee Termination Cost-related Amounts			-	(0.01)				
Litigation-related Charge		-		0.04				
Dilutive Share Impact		-		0.02				
Adjusted Fully Diluted Earnings per Share	=== \$	8.37 - 8.44		===== \$7.16		17.0% - 18.0%		
FX Impact		\$(0.36)				(5.0%)		
Adjusted FXN Growth	=== \$	8.73 - 8.80				22.0% - 23.0%		
Organic Revenues Growth								
	Q1	Q2	Q3	Q4	Full Year	Full Year		
	---	---	---	---	FY2015	FY2016		
					(estimated)			
CareFusion Revenues, Reported		16.1%	3.0%		(5.2%)	1.2%	3.3%	
FX Impact		(1.4%)	(2.4%)		(3.2%)	(2.8%)	(2.5%)	~(0.5%)
CareFusion Revenues, FXN		17.5%	5.4%		(2.0%)	4.0%	5.8%	
CareFusion Inorganic Revenues, FXN	---	(7.6%)	-		(0.2%)	(0.6%)	(2.0%)	~1.5%
CareFusion Organic Revenues, FXN (1)		9.9%	5.4%		(2.2%)	3.4%	3.8%	
BD Standalone Revenues, Reported		1.8%	(1.0%)		(4.1%)	(3.1%)	(1.7%)	

FX Impact	(3.5%)	(5.9%)	(8.7%)	(8.6%)	(6.8%)	~(2.0%)
BD Standalone Revenues, FXN	5.3%	4.9%	4.7%	5.5%	5.1%	
BD Standalone Inorganic Revenues, FXN	NM	NM	(0.1%)	NM	NM	NM
BD Standalone Organic Revenues, FXN	5.3%	4.9%	4.6%	5.5%	5.1%	
CareFusion Organic Revenues, FXN(1)				3.8%	~4.0%	
BD Standalone Organic Revenues, FXN				5.1%	~5.0%	
BD Including CareFusion Organic Revenues, FXN				4.7%	4.5%-5.0%	

NM - Not Meaningful

FXN = Foreign Currency Neutral

(1) Excludes the impact from a distribution agreement change in the Respiratory Solutions business.

Contact:

Monique N. Dolecki, Investor Relations - 201-847-5453

Kristen Cardillo, Corporate Communications - 858-617-2317

To view the original version on PR Newswire, visit <http://www.prnewswire.com/news-releases/bd-announces-results-for-2015-fourth-fiscal-quarter-and-full-year-provides-fiscal-2016-guidance-300171925.html>

SOURCE BD (Becton, Dickinson and Company)

<https://news.bd.com/2015-11-04-BD-Announces-Results-For-2015-Fourth-Fiscal-Quarter-And-Full-Year-Provides-Fiscal-2016-Guidance>